Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 689-698    DOI: 10.31083/j.ejgo.2020.05.5437
Original Research Previous articles | Next articles
Phenotypic differences of tecidual TDCs obtained from breast cancer mice
Polyana Barbosa Silva1, Millena Prata Jammal1, 3, Márcia Antoniazi Michelin1, 2, Eddie Fernando Cândido Murta1, 3, *()
1Reseach Institute of Oncology (IPON) - Federal University of The Triângulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil
2Discipline of Immunology, Federal University of The Triângulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil
3Discipline of Gynecology and Obstetrics, Federal University of The Triângulo Mineiro (UFTM), Uberaba, Minas Gerais, Brazil
Download:  PDF(711KB)  ( 162 ) Full text   ( 9 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To evaluate TDC expression by flow cytometry for surface markers (CD4, CD8 and CD86), transcription factors (Tbet, Foxp3, Gata3 and Rorγt), and cytokines (IFN-γ, TNF-α, IL-10, IL-12 and IL-17) in spleen, liver, lymph node, bone marrow and tumor of 4T1 induced and healthy mice. Results: TDC are more frequent in lymph nodes in the control and tumor groups, compared to the other environments studied (p < 0.0001). When we compare the expression of surface markers between control and 4T1 induced groupswe noted decreased CD4 TDC expression in liver (p = 0.0001), and the same with CD8 TDC expression in spleen (p = 0.0012) and liver (p = 0.0028), as well as the expression of CD86 TDC in spleen and liver (p = 0.0337), in the 4T1-induced tumor group. When comparing transcription factors, there was a decrease TDC Tbet and TDC Foxp3 in spleen and liver (p = 0.0001); and the same with TDC Gata3 in liver (p = 0.0028), and increase in TDC Rorγt in bone marrow in the tumor group (p < 0.0001). Regarding cytokines, we found decreased IFN-γ TDC in spleen (p < 0.0001) and bone marrow (p = 0.0002), and the same with TNF-α TDC in spleen and liver (p < 0.0001), as well as the expression of IL-10 TDC in spleen (p < 0.0001), liver (p < 0.0001) and bone marrow (p < 0,001), of IL-12 TDC in spleen and bone marrow (p < 0,001), and IL-17 TDC in spleen and liver (p < 0,001) in the 4T1-induced tumor group in all comparisons.Phenotypic changes may be driven by the tissue microenvironment in the presence of the tumor. Directions are needed to understand the functionality associated with possible antitumor immunotherapy.
Key words:  TDC cells      Breast cancer      Tissue microenvironment      Antitumor immune response     
Submitted:  21 November 2019      Accepted:  03 April 2020      Published:  15 October 2020     
Fund: 
30211/2015-3/National Council for Scientific and Technological Development
255/2012/Education Foundation and Uberaba Research
Higher Education Personnel Improvement Coordination
Rede 11/14/Research Support Foundation Minas Gerais state
*Corresponding Author(s):  EDDIE FERNANDO CÂNDIDO MURTA     E-mail:  eddiemurta@mednet.com.br

Cite this article: 

Polyana Barbosa Silva, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Cândido Murta. Phenotypic differences of tecidual TDCs obtained from breast cancer mice. European Journal of Gynaecological Oncology, 2020, 41(5): 689-698.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5437     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/689

[1] Huifen Zhen, Fan Guo, Xiaojun Zhang, Miaomiao Jia, Haibo Yang, Yarong Yao, Yuandong Li, Jinnan Gao. The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 785-789.
[2] Katselashvili Lika, Jokhadze Natia, Katcharava Margarita, Vardiashvili Nino. Breast Cancer Metastatic to Vulva - a Case Report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 845-848.
[3] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[4] Isao Otsuka. Clear cell carcinoma of the vagina followed by breast cancer in a patient without prenatal diethylstilbestrol exposure[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 638-639.
[5] Luca Roncati, Maria Vadalà, Pepe Valentina, Veronica Corazzari, Beniamino Palmieri. Genomic profiling in gynaecological oncology: the future is now![J]. European Journal of Gynaecological Oncology, 2020, 41(3): 323-325.
[6] D. Korfias, J. Contis, M. Frangou-Plemenou, K. Gennatas, A. Kondis, D. Vlachodimitropoulos. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 36-41.
[7] A. Conversano, C. Balleyguier, M.K. De Fremicourt, H. Alkhashnam, C. Mazouni, J. Arfi-Rouche, N. Leymarie, F. Rimareix. Magnetic seed localisation for non-palpable lesions in patients undergoing breast conservative surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 48-53.
[8] S.Wang, W.J. Chen, Z.M. Song, Q. Li, X. Shen, Y.D. Wu, L. Zhu, Q.X. Ma, D.M. Xing. Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 106-109.
[9] M. Englert-Golon, B. Burchardt, R. Słopień, N. Smolarek, S. Sajdak. Ovarian and endometrial cancer after breast cancer - three primary malignancies in a single patient[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 153-154.
[10] T. Aizawa, T. Maebayashi, N. Ishibashi, M. Sakaguchi. Bilateral organizing pneumonia after radiotherapy for bilateral synchronous breast cancers: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1051-1054.
[11] M. El Homsi, A. Barakat, R. Rammal, M. Haidar. Uterine metastasis from invasive ductal breast carcinoma mimicking fibroid features on MRI and detected by FDG PET/CT: role of SUVmax[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1079-1082.
[12] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
[13] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781-786.
[14] S. Bertozzi, A. P. Londero, S. Bernardi, C. Cedolini. Applicability of the Notthingham Prognostic Index for predicting the survival of triple-negative invasive breast cancer in a single Italian center[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 787-790.
[15] C. Cedolini, S. Bertozzi, A. P. Londero, I. Pradelle, S. Bernardi, V. Londero, A. Uzzau, M. Bazzocchi, C. Zuiani, A. Risaliti. Risk factors for breast cancer development in patients with borderline breast lesions: a retrospective analysis of our outpatient facility[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 572-578.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Akanksha Agrawal, Deepanshu Jain, Pradhum Ram, Jorge Luis Penalver Leon, Janani Rangaswami. Anticoagulation for intra-cardiac thrombi in peripartum cardiomyopathy: A review of the literature[J]. Reviews in Cardiovascular Medicine, 2019, 20(2): 53 -58 .
[3] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[4] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[5] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[6] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[7] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[8] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[9] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[10] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .